Trial reportJournal of hypertension2026
Chronic plateau exposure attenuates antihypertensive efficacy in highlanders: insights from the OMAN trial.
Trial report in Journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidemiological studies indicate that the unique high-altitude environment may promote the prevalence of hypertension. Nevertheless, whether chronic plateau exposure affects antihypertensive efficacy in hypertensive highlanders remains unknown.
methodsThis is a post hoc analysis of the OMAN Trial, a randomized controlled study that compared the antihypertensive efficacy of morning versus bedtime administration of olmesartan/amlodipine. Hypertensive patients from the OMAN Trial were stratified into highlanders (Sichuan-Tibet Plateau, altitude ≈ 3000 m) and lowlanders (Sichuan-Chengdu Plain, altitude ≈ 500 m) based on 1 : 1 propensity score matching. After 4-week treatment of olmesartan/amlodipine (20/5 mg once daily), between-group differences in office/ambulatory blood pressure (BP) reduction, control rates, and rhythms were analyzed.
resultsEach group comprised 171 hypertensive patients with balanced baselines. While office BP reductions were comparable between groups, highlanders showed significantly smaller reductions in 24-h ambulatory BP compared with lowlanders (between-group difference in 24-h SBP reduction: -2.39 mmHg, P = 0.048; between-group difference in 24-h DBP reduction: -1.60 mmHg, P = 0.025). More pronounced between-group differences in BP reduction were observed during the morning (ΔSBP: -7.18 mmHg, P < 0.001; ΔDBP: -4.01 mmHg, P = 0.002) and daytime (ΔSBP: -3.81 mmHg, P = 0.005; ΔDBP: -2.29 mmHg, P = 0.005) periods. Similarly, both office BP control (lowlanders: 77.2% vs. highlanders: 60.2%, P = 0.001) and 24-h BP control rates (lowlanders: 50.9% vs. highlanders: 34.5%, P = 0.002) were significantly lower in highlanders. Intriguingly, nocturnal BP reduction and control rates showed no significant intergroup differences.
conclusionOur findings suggest chronic plateau exposure may attenuate antihypertensive efficacy, potentially necessitating intensified treatment regimens for BP control in highlanders. REGISTRATION: URL: https://www.chictr.org.cn/ ; Registration number: ChiCTR2200059719.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.